157 related articles for article (PubMed ID: 2399526)
1. Adenosine potentiates the inhibitory effects of calcium channel antagonists on human platelet aggregation induced by thromboxane A2 or U46619.
Johnson GJ; Leis LA; Francis GS
Thromb Res; 1990 Jul; 59(1):139-48. PubMed ID: 2399526
[TBL] [Abstract][Full Text] [Related]
2. Disparate effects of the calcium-channel blockers, nifedipine and verapamil, on alpha 2-adrenergic receptors and thromboxane A2-induced aggregation of human platelets.
Johnson GJ; Leis LA; Francis GS
Circulation; 1986 Apr; 73(4):847-54. PubMed ID: 3004784
[TBL] [Abstract][Full Text] [Related]
3. Antithrombogenic effects of calcium channel blockers: synergism with prostacyclin and thromboxane synthase inhibitors.
Onoda JM; Sloane BF; Honn KV
Thromb Res; 1984 Jun; 34(5):367-78. PubMed ID: 6377570
[TBL] [Abstract][Full Text] [Related]
4. Dihydropyridine agonist Bay K 8644 inhibits platelet activation by competitive antagonism of thromboxane A2-prostaglandin H2 receptor.
Johnson GJ; Dunlop PC; Leis LA; From AH
Circ Res; 1988 Mar; 62(3):494-505. PubMed ID: 2449295
[TBL] [Abstract][Full Text] [Related]
5. Influence of verapamil and diltiazem on aggregatory responses in cat and rabbit platelet rich plasma.
Lippton HL; Horwitz PM; McNamara DB; Landry AZ; Kadowitz PJ
Prostaglandins Leukot Med; 1984 Oct; 16(1):121-30. PubMed ID: 6440150
[TBL] [Abstract][Full Text] [Related]
6. In vitro effects of two novel calcium antagonists (nitrendipine and nisoldipine) on intraplatelet calcium redistribution, platelet aggregation and thromboxane A2 formation. Comparison with diltiazem, nifedipine and verapamil.
Rostagno C; Abbate R; Gensini GF; Coppo M; Prisco D; Boddi M; Neri Serneri GG
Thromb Res; 1991 Aug; 63(4):457-62. PubMed ID: 1754998
[No Abstract] [Full Text] [Related]
7. Effects of calcium channel blockers on platelet aggregation and thromboxane A2 formation: an in vivo double blind randomized study.
Rostagno C; Prisco D; Paniccia R; Costanzo G; Poggesi L; Boddi M; Abbate R
Thromb Res; 1990 Aug; 59(3):531-9. PubMed ID: 2237825
[TBL] [Abstract][Full Text] [Related]
8. Effects of prostaglandins, cAMP, and changes in cytosolic calcium on platelet aggregation induced by a thromboxane A2 mimic (U46619).
Yun JC; Ohman KP; Gill JR; Keiser H
Can J Physiol Pharmacol; 1991 May; 69(5):599-604. PubMed ID: 1650650
[TBL] [Abstract][Full Text] [Related]
9. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
Shaw LA; Batey AJ; Coker SJ
Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543
[TBL] [Abstract][Full Text] [Related]
10. Antagonism of U46619-induced aggregation of human and canine platelets by four TXA2 receptor antagonists.
Bush LR; Smith SG
Thromb Res; 1986 Nov; 44(3):377-89. PubMed ID: 2948294
[TBL] [Abstract][Full Text] [Related]
11. Verapamil is a potent inhibitor of 5-HT-induced platelet aggregation.
Glusa E; Bevan J; Heptinstall S
Thromb Res; 1989 Jul; 55(2):239-245. PubMed ID: 2528843
[TBL] [Abstract][Full Text] [Related]
12. Dual effects of nimesulide, a COX-2 inhibitor, in human platelets.
Saeed SA; Afzal MN; Shah BH
Life Sci; 1998; 63(20):1835-41. PubMed ID: 9820127
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of endothelial cells and calcium channel blockers on platelet aggregation.
Yamada Y; Furui H; Furumichi T; Suzuki T; Yamauchi K; Yokota M; Hayashi H; Saito H
Jpn Heart J; 1990 Mar; 31(2):201-15. PubMed ID: 2113109
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human platelet aggregation and cytoplasmic calcium response by calcium antagonists: studies with aequorin and quin2.
Ware JA; Johnson PC; Smith M; Salzman EW
Circ Res; 1986 Jul; 59(1):39-42. PubMed ID: 3089642
[TBL] [Abstract][Full Text] [Related]
15. Calcium channel blocker treatment of tumor cells induces alterations in the cytoskeleton, mobility of the integrin alpha IIb beta 3 and tumor-cell-induced platelet aggregation.
Timar J; Chopra H; Rong X; Hatfield JS; Fligiel SE; Onoda JM; Taylor JD; Honn KV
J Cancer Res Clin Oncol; 1992; 118(6):425-34. PubMed ID: 1377695
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the inhibition of U46619-mediated human platelet activation by the trimetoquinol isomers. Evidence for endoperoxide/thromboxane A2 receptor blockade.
Ahn CH; Romstedt KJ; Wallace LJ; Miller DD; Feller DR
Biochem Pharmacol; 1988 Aug; 37(15):3023-33. PubMed ID: 3134894
[TBL] [Abstract][Full Text] [Related]
17. Effects of some calcium antagonists on aggregation by adrenalin and serotonin and on alpha-adrenoceptor radioligand binding in human platelets.
Vinge E; Andersson TL; Larsson B
Acta Physiol Scand; 1988 Jul; 133(3):407-16. PubMed ID: 2906509
[TBL] [Abstract][Full Text] [Related]
18. Comparison of verapamil and nifedipine in thrombosis models.
Myers AK; Forman G; Torres Duarte AP; Penhos J; Ramwell P
Proc Soc Exp Biol Med; 1986 Oct; 183(1):86-91. PubMed ID: 3092231
[TBL] [Abstract][Full Text] [Related]
19. Influence of nifedipine, verapamil and diltiazem on pulmonary vascular resistance and vasoconstrictors in cats.
Erdemli O; Hao Q; Cai B; Lippton HL; Hyman A
Arch Int Pharmacodyn Ther; 1994; 328(2):165-79. PubMed ID: 7535994
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of rabbit platelet phosphodiesterase activity and aggregation by calcium channel blockers.
Moore JB; Fuller BL; Falotico R; Tolman EL
Thromb Res; 1985 Nov; 40(3):401-11. PubMed ID: 2417362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]